Polygenic Score (PGS) ID: PGS000907

Predicted Trait
Reported Trait Major depressive disorder
Mapped Trait(s) major depressive disorder (MONDO_0002009)
Released in PGS Catalog: Oct. 7, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRS_MDD
Development Method
Name SBayesR
Parameters --ldm ldm_ukb_50k_bigset_2.8M\ --pi 0.95,0.02,0.02,0.01 \ --gamma 0.0,0.01,0.1,1 \ --chain-length 25000 \ --burn-in 5000 \ --out-freq 10 \
Variants
Original Genome Build hg19
Number of Variants 1,773,528
Effect Weight Type NR
PGS Source
PGS Catalog Publication (PGP) ID PGP000238
Citation (link to publication) Campos AI et al. medRxiv (2021) Preprint
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
322,580 individuals (100%)
PGS Evaluation
European: 100%
250 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST005902
Europe PMC: 29662059
322,580 individuals European NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002681 PSS001279|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Escitalopram takers OR: 1.0 [0.92, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002682 PSS001284|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Venlafaxine takers OR: 1.05 [0.96, 1.15] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002684 PSS001281|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Mirtazapine takers OR: 1.05 [0.91, 1.22] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002685 PSS001277|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Desvenlafaxine takers OR: 1.01 [0.91, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002686 PSS001276|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Citalopram takers OR: 1.02 [0.9, 1.16] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002687 PSS001280|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Fluoxetine takers OR: 1.06 [0.96, 1.17] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002688 PSS001278|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Duloxetine takers OR: 1.06 [0.95, 1.2] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002689 PSS001282|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Paroxetine takers OR: 1.08 [0.92, 1.26] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002690 PSS001243|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Sertraline takers OR: 1.06 [0.98, 1.14] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002691 PSS001239|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Escitalopram takers OR: 1.06 [0.98, 1.15] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002692 PSS001244|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Venlafaxine takers OR: 1.01 [0.93, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002693 PSS001235|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Amitriptyline takers OR: 0.96 [0.83, 1.1] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002694 PSS001241|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Mirtazapine takers OR: 1.07 [0.93, 1.23] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002695 PSS001237|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Desvenlafaxine takers OR: 0.97 [0.87, 1.07] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002696 PSS001236|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Citalopram takers OR: 0.99 [0.87, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002697 PSS001240|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Fluoxetine takers OR: 1.16 [1.04, 1.29] Variance explained (Nagelkerke's R2*100): 0.41 sex, age at study enrollment, genetic PCs 1-20
PPM002698 PSS001238|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Duloxetine takers OR: 0.98 [0.88, 1.1] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002699 PSS001242|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dizziness in Paroxetine takers OR: 1.08 [0.93, 1.24] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002700 PSS001373|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Sertraline takers OR: 1.03 [0.94, 1.12] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002701 PSS001369|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Escitalopram takers OR: 1.01 [0.9, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002702 PSS001374|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Venlafaxine takers OR: 1.1 [1.0, 1.22] Variance explained (Nagelkerke's R2*100): 0.18 sex, age at study enrollment, genetic PCs 1-20
PPM002703 PSS001365|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Amitriptyline takers OR: 0.99 [0.81, 1.2] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002704 PSS001371|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Mirtazapine takers OR: 1.03 [0.86, 1.24] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002705 PSS001367|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Desvenlafaxine takers OR: 1.04 [0.92, 1.18] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002707 PSS001370|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Fluoxetine takers OR: 1.06 [0.95, 1.19] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002708 PSS001368|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Duloxetine takers OR: 0.9 [0.79, 1.04] Variance explained (Nagelkerke's R2*100): 0.21 sex, age at study enrollment, genetic PCs 1-20
PPM002709 PSS001372|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Paroxetine takers OR: 1.19 [1.0, 1.41] Variance explained (Nagelkerke's R2*100): 0.53 sex, age at study enrollment, genetic PCs 1-20
PPM002710 PSS001303|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Sertraline takers OR: 1.13 [0.97, 1.31] Variance explained (Nagelkerke's R2*100): 0.18 sex, age at study enrollment, genetic PCs 1-20
PPM002711 PSS001299|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Escitalopram takers OR: 0.96 [0.8, 1.14] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002712 PSS001304|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Venlafaxine takers OR: 1.22 [1.03, 1.45] Variance explained (Nagelkerke's R2*100): 0.51 sex, age at study enrollment, genetic PCs 1-20
PPM002713 PSS001295|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Amitriptyline takers OR: 1.06 [0.8, 1.4] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002715 PSS001297|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Desvenlafaxine takers OR: 1.0 [0.8, 1.24] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002716 PSS001296|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Citalopram takers OR: 0.95 [0.72, 1.27] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002717 PSS001300|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Fluoxetine takers OR: 1.3 [1.05, 1.6] Variance explained (Nagelkerke's R2*100): 0.77 sex, age at study enrollment, genetic PCs 1-20
PPM002718 PSS001298|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Duloxetine takers OR: 0.99 [0.82, 1.2] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002720 PSS001263|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Sertraline takers OR: 1.04 [0.98, 1.11] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002721 PSS001259|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Escitalopram takers OR: 1.01 [0.94, 1.09] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002722 PSS001264|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Venlafaxine takers OR: 0.98 [0.91, 1.05] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002723 PSS001255|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Amitriptyline takers OR: 1.06 [0.95, 1.17] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002724 PSS001261|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Mirtazapine takers OR: 1.05 [0.94, 1.17] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002725 PSS001257|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Desvenlafaxine takers OR: 1.09 [0.99, 1.2] Variance explained (Nagelkerke's R2*100): 0.2 sex, age at study enrollment, genetic PCs 1-20
PPM002726 PSS001256|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Citalopram takers OR: 1.11 [1.0, 1.23] Variance explained (Nagelkerke's R2*100): 0.23 sex, age at study enrollment, genetic PCs 1-20
PPM002727 PSS001260|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Fluoxetine takers OR: 1.0 [0.92, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002728 PSS001258|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Duloxetine takers OR: 1.03 [0.93, 1.13] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002729 PSS001262|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Dry mouth in Paroxetine takers OR: 0.98 [0.86, 1.1] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002730 PSS001403|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Sertraline takers OR: 0.99 [0.92, 1.07] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002731 PSS001399|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Escitalopram takers OR: 0.97 [0.89, 1.06] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002732 PSS001404|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Venlafaxine takers OR: 1.04 [0.96, 1.12] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002733 PSS001395|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Amitriptyline takers OR: 1.14 [0.96, 1.37] Variance explained (Nagelkerke's R2*100): 0.3 sex, age at study enrollment, genetic PCs 1-20
PPM002734 PSS001401|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Mirtazapine takers OR: 1.05 [0.9, 1.22] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002735 PSS001397|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Desvenlafaxine takers OR: 0.99 [0.9, 1.1] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002736 PSS001396|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Citalopram takers OR: 1.14 [0.99, 1.3] Variance explained (Nagelkerke's R2*100): 0.29 sex, age at study enrollment, genetic PCs 1-20
PPM002737 PSS001400|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Fluoxetine takers OR: 1.04 [0.94, 1.16] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002738 PSS001398|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Duloxetine takers OR: 0.96 [0.86, 1.07] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002739 PSS001402|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Sweating in Paroxetine takers OR: 1.1 [0.94, 1.28] Variance explained (Nagelkerke's R2*100): 0.17 sex, age at study enrollment, genetic PCs 1-20
PPM002741 PSS001309|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Escitalopram takers OR: 1.06 [0.98, 1.15] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002742 PSS001314|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Venlafaxine takers OR: 1.08 [1.0, 1.17] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002743 PSS001305|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Amitriptyline takers OR: 1.12 [0.95, 1.31] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002744 PSS001311|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Mirtazapine takers OR: 1.08 [0.93, 1.25] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002745 PSS001307|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Desvenlafaxine takers OR: 1.06 [0.96, 1.17] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002746 PSS001306|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Citalopram takers OR: 1.11 [0.99, 1.25] Variance explained (Nagelkerke's R2*100): 0.24 sex, age at study enrollment, genetic PCs 1-20
PPM002747 PSS001310|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Fluoxetine takers OR: 1.06 [0.97, 1.16] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002748 PSS001308|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Duloxetine takers OR: 1.16 [1.04, 1.29] Variance explained (Nagelkerke's R2*100): 0.55 sex, age at study enrollment, genetic PCs 1-20
PPM002749 PSS001312|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Paroxetine takers OR: 1.1 [0.96, 1.27] Variance explained (Nagelkerke's R2*100): 0.21 sex, age at study enrollment, genetic PCs 1-20
PPM002750 PSS001423|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Sertraline takers OR: 1.21 [1.03, 1.43] Variance explained (Nagelkerke's R2*100): 0.44 sex, age at study enrollment, genetic PCs 1-20
PPM002751 PSS001419|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Escitalopram takers OR: 0.96 [0.78, 1.18] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002752 PSS001424|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Venlafaxine takers OR: 1.14 [0.96, 1.36] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002754 PSS001421|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Mirtazapine takers OR: 1.23 [0.88, 1.72] Variance explained (Nagelkerke's R2*100): 0.45 sex, age at study enrollment, genetic PCs 1-20
PPM002755 PSS001417|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Desvenlafaxine takers OR: 1.08 [0.86, 1.36] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002756 PSS001416|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Citalopram takers OR: 1.19 [0.87, 1.64] Variance explained (Nagelkerke's R2*100): 0.32 sex, age at study enrollment, genetic PCs 1-20
PPM002757 PSS001420|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Fluoxetine takers OR: 1.01 [0.8, 1.28] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002758 PSS001418|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Duloxetine takers OR: 1.09 [0.87, 1.35] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002759 PSS001422|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Paroxetine takers OR: 1.17 [0.86, 1.61] Variance explained (Nagelkerke's R2*100): 0.3 sex, age at study enrollment, genetic PCs 1-20
PPM002760 PSS001223|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Sertraline takers OR: 1.15 [1.03, 1.29] Variance explained (Nagelkerke's R2*100): 0.29 sex, age at study enrollment, genetic PCs 1-20
PPM002761 PSS001219|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Escitalopram takers OR: 1.16 [1.01, 1.33] Variance explained (Nagelkerke's R2*100): 0.32 sex, age at study enrollment, genetic PCs 1-20
PPM002762 PSS001224|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Venlafaxine takers OR: 1.19 [1.07, 1.34] Variance explained (Nagelkerke's R2*100): 0.54 sex, age at study enrollment, genetic PCs 1-20
PPM002763 PSS001215|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Amitriptyline takers OR: 1.16 [0.98, 1.37] Variance explained (Nagelkerke's R2*100): 0.38 sex, age at study enrollment, genetic PCs 1-20
PPM002764 PSS001221|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Mirtazapine takers OR: 1.08 [0.89, 1.29] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002765 PSS001217|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Desvenlafaxine takers OR: 1.03 [0.89, 1.2] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002767 PSS001220|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Fluoxetine takers OR: 1.09 [0.94, 1.27] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002768 PSS001218|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Duloxetine takers OR: 1.02 [0.89, 1.18] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002769 PSS001222|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Paroxetine takers OR: 1.09 [0.9, 1.31] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002771 PSS001229|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Escitalopram takers OR: 1.01 [0.89, 1.16] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002772 PSS001234|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Venlafaxine takers OR: 1.13 [0.97, 1.32] Variance explained (Nagelkerke's R2*100): 0.2 sex, age at study enrollment, genetic PCs 1-20
PPM002773 PSS001225|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Amitriptyline takers OR: 1.02 [0.73, 1.42] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002774 PSS001231|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Mirtazapine takers OR: 1.13 [0.89, 1.42] Variance explained (Nagelkerke's R2*100): 0.18 sex, age at study enrollment, genetic PCs 1-20
PPM002775 PSS001227|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Desvenlafaxine takers OR: 1.01 [0.84, 1.21] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002776 PSS001226|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Citalopram takers OR: 0.95 [0.76, 1.19] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002777 PSS001230|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Fluoxetine takers OR: 0.99 [0.84, 1.17] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002778 PSS001228|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Duloxetine takers OR: 1.08 [0.9, 1.3] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002779 PSS001232|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Paroxetine takers OR: 1.47 [1.13, 1.91] Variance explained (Nagelkerke's R2*100): 1.92 sex, age at study enrollment, genetic PCs 1-20
PPM002780 PSS001253|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Sertraline takers OR: 1.01 [0.94, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002782 PSS001254|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Venlafaxine takers OR: 1.0 [0.91, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002783 PSS001245|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Amitriptyline takers OR: 0.99 [0.89, 1.11] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002784 PSS001251|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Mirtazapine takers OR: 1.06 [0.96, 1.18] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002785 PSS001247|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Desvenlafaxine takers OR: 0.99 [0.88, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002786 PSS001246|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Citalopram takers OR: 1.05 [0.93, 1.18] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002787 PSS001250|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Fluoxetine takers OR: 1.04 [0.94, 1.14] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002788 PSS001248|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Duloxetine takers OR: 0.96 [0.86, 1.08] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002789 PSS001252|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Paroxetine takers OR: 0.97 [0.83, 1.12] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002790 PSS001413|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Sertraline takers OR: 1.04 [0.97, 1.12] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002791 PSS001409|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Escitalopram takers OR: 1.02 [0.94, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002792 PSS001414|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Venlafaxine takers OR: 1.02 [0.94, 1.1] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002793 PSS001405|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Amitriptyline takers OR: 1.05 [0.88, 1.26] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002794 PSS001411|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Mirtazapine takers OR: 1.13 [0.97, 1.32] Variance explained (Nagelkerke's R2*100): 0.27 sex, age at study enrollment, genetic PCs 1-20
PPM002795 PSS001407|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Desvenlafaxine takers OR: 1.05 [0.95, 1.16] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002796 PSS001406|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Citalopram takers OR: 1.0 [0.89, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002797 PSS001410|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Fluoxetine takers OR: 1.05 [0.96, 1.15] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002798 PSS001408|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Duloxetine takers OR: 0.97 [0.87, 1.09] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002800 PSS001203|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Sertraline takers OR: 1.13 [1.04, 1.22] Variance explained (Nagelkerke's R2*100): 0.29 sex, age at study enrollment, genetic PCs 1-20
PPM002801 PSS001199|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Escitalopram takers OR: 1.01 [0.91, 1.11] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002802 PSS001204|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Venlafaxine takers OR: 1.14 [1.04, 1.26] Variance explained (Nagelkerke's R2*100): 0.36 sex, age at study enrollment, genetic PCs 1-20
PPM002803 PSS001195|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Amitriptyline takers OR: 1.05 [0.87, 1.27] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002804 PSS001201|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Mirtazapine takers OR: 1.2 [1.03, 1.39] Variance explained (Nagelkerke's R2*100): 0.59 sex, age at study enrollment, genetic PCs 1-20
PPM002805 PSS001197|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Desvenlafaxine takers OR: 1.04 [0.92, 1.17] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002806 PSS001196|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Citalopram takers OR: 0.97 [0.85, 1.12] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002807 PSS001200|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Fluoxetine takers OR: 1.05 [0.96, 1.16] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002808 PSS001198|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Duloxetine takers OR: 1.0 [0.87, 1.14] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002809 PSS001202|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Anxiety in Paroxetine takers OR: 1.1 [0.94, 1.29] Variance explained (Nagelkerke's R2*100): 0.19 sex, age at study enrollment, genetic PCs 1-20
PPM002810 PSS001193|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Sertraline takers OR: 1.04 [0.96, 1.13] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002811 PSS001189|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Escitalopram takers OR: 1.06 [0.96, 1.17] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002812 PSS001194|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Venlafaxine takers OR: 1.06 [0.97, 1.17] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002813 PSS001185|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Amitriptyline takers OR: 1.02 [0.85, 1.23] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002814 PSS001191|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Mirtazapine takers OR: 1.25 [1.08, 1.46] Variance explained (Nagelkerke's R2*100): 0.93 sex, age at study enrollment, genetic PCs 1-20
PPM002816 PSS001186|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Citalopram takers OR: 1.05 [0.91, 1.21] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002817 PSS001190|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Fluoxetine takers OR: 1.06 [0.96, 1.18] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002818 PSS001188|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Duloxetine takers OR: 1.05 [0.91, 1.21] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002819 PSS001192|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Paroxetine takers OR: 1.19 [1.02, 1.38] Variance explained (Nagelkerke's R2*100): 0.6 sex, age at study enrollment, genetic PCs 1-20
PPM002820 PSS001273|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Sertraline takers OR: 1.01 [0.94, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002821 PSS001269|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Escitalopram takers OR: 0.96 [0.88, 1.05] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002822 PSS001274|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Venlafaxine takers OR: 1.06 [0.97, 1.16] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002823 PSS001265|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Amitriptyline takers OR: 1.12 [0.97, 1.28] Variance explained (Nagelkerke's R2*100): 0.25 sex, age at study enrollment, genetic PCs 1-20
PPM002824 PSS001271|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Mirtazapine takers OR: 1.06 [0.94, 1.2] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002826 PSS001266|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Citalopram takers OR: 0.98 [0.86, 1.11] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002827 PSS001270|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Fluoxetine takers OR: 1.02 [0.92, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002829 PSS001272|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Paroxetine takers OR: 0.96 [0.82, 1.11] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002831 PSS001429|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Escitalopram takers OR: 1.04 [0.97, 1.11] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002832 PSS001434|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Venlafaxine takers OR: 1.03 [0.96, 1.11] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002833 PSS001425|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Amitriptyline takers OR: 1.06 [0.95, 1.19] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002834 PSS001431|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Mirtazapine takers OR: 1.02 [0.93, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002835 PSS001427|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Desvenlafaxine takers OR: 1.11 [1.02, 1.22] Variance explained (Nagelkerke's R2*100): 0.33 sex, age at study enrollment, genetic PCs 1-20
PPM002836 PSS001426|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Citalopram takers OR: 1.14 [1.03, 1.25] Variance explained (Nagelkerke's R2*100): 0.4 sex, age at study enrollment, genetic PCs 1-20
PPM002837 PSS001430|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Fluoxetine takers OR: 1.04 [0.96, 1.12] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002838 PSS001428|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Duloxetine takers OR: 1.0 [0.91, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002839 PSS001432|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Paroxetine takers OR: 1.11 [0.99, 1.24] Variance explained (Nagelkerke's R2*100): 0.28 sex, age at study enrollment, genetic PCs 1-20
PPM002840 PSS001443|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Sertraline takers OR: 0.9 [0.75, 1.07] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002841 PSS001439|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Escitalopram takers OR: 1.07 [0.88, 1.32] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002842 PSS001444|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Venlafaxine takers OR: 1.05 [0.84, 1.3] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002844 PSS001441|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Mirtazapine takers OR: 1.21 [0.85, 1.71] Variance explained (Nagelkerke's R2*100): 0.37 sex, age at study enrollment, genetic PCs 1-20
PPM002845 PSS001437|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Desvenlafaxine takers OR: 0.95 [0.74, 1.22] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002846 PSS001436|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Citalopram takers OR: 0.87 [0.61, 1.23] Variance explained (Nagelkerke's R2*100): 0.19 sex, age at study enrollment, genetic PCs 1-20
PPM002847 PSS001440|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Fluoxetine takers OR: 1.16 [0.96, 1.39] Variance explained (Nagelkerke's R2*100): 0.26 sex, age at study enrollment, genetic PCs 1-20
PPM002848 PSS001438|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Duloxetine takers OR: 0.96 [0.75, 1.23] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002849 PSS001442|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Paroxetine takers OR: 1.36 [0.88, 2.1] Variance explained (Nagelkerke's R2*100): 0.99 sex, age at study enrollment, genetic PCs 1-20
PPM002852 PSS001344|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Venlafaxine takers OR: 1.0 [0.74, 1.36] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002853 PSS001335|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Amitriptyline takers OR: 1.22 [0.73, 2.04] Variance explained (Nagelkerke's R2*100): 0.42 sex, age at study enrollment, genetic PCs 1-20
PPM002854 PSS001341|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Mirtazapine takers OR: 1.0 [0.65, 1.52] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002855 PSS001337|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Desvenlafaxine takers OR: 1.58 [1.13, 2.23] Variance explained (Nagelkerke's R2*100): 2.19 sex, age at study enrollment, genetic PCs 1-20
PPM002856 PSS001336|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Citalopram takers OR: 1.1 [0.7, 1.74] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002857 PSS001340|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Fluoxetine takers OR: 1.34 [0.91, 1.97] Variance explained (Nagelkerke's R2*100): 0.75 sex, age at study enrollment, genetic PCs 1-20
PPM002858 PSS001338|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Duloxetine takers OR: 1.13 [0.75, 1.7] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002859 PSS001342|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Paroxetine takers OR: 1.16 [0.69, 1.95] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002860 PSS001363|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Sertraline takers OR: 1.0 [0.79, 1.28] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002861 PSS001359|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Escitalopram takers OR: 0.91 [0.69, 1.19] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002862 PSS001364|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Venlafaxine takers OR: 1.06 [0.8, 1.42] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002863 PSS001355|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Amitriptyline takers OR: 0.59 [0.36, 0.98] Variance explained (Nagelkerke's R2*100): 2.43 sex, age at study enrollment, genetic PCs 1-20
PPM002864 PSS001361|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Mirtazapine takers OR: 0.85 [0.55, 1.3] Variance explained (Nagelkerke's R2*100): 0.25 sex, age at study enrollment, genetic PCs 1-20
PPM002865 PSS001357|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Desvenlafaxine takers OR: 0.8 [0.59, 1.07] Variance explained (Nagelkerke's R2*100): 0.58 sex, age at study enrollment, genetic PCs 1-20
PPM002868 PSS001358|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Duloxetine takers OR: 0.99 [0.71, 1.38] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002869 PSS001362|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Paroxetine takers OR: 0.9 [0.53, 1.52] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002870 PSS001353|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Sertraline takers OR: 1.0 [0.95, 1.06] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002871 PSS001349|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Escitalopram takers OR: 0.99 [0.93, 1.06] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002872 PSS001354|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Venlafaxine takers OR: 1.05 [0.99, 1.13] Variance explained (Nagelkerke's R2*100): 0.09 sex, age at study enrollment, genetic PCs 1-20
PPM002873 PSS001345|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Amitriptyline takers OR: 1.08 [0.96, 1.22] Variance explained (Nagelkerke's R2*100): 0.16 sex, age at study enrollment, genetic PCs 1-20
PPM002878 PSS001348|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Duloxetine takers OR: 0.99 [0.91, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002879 PSS001352|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Paroxetine takers OR: 1.0 [0.9, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002883 PSS001205|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Amitriptyline takers OR: 1.08 [0.86, 1.36] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002884 PSS001211|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Mirtazapine takers OR: 1.05 [0.84, 1.31] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002885 PSS001207|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Desvenlafaxine takers OR: 1.13 [0.94, 1.37] Variance explained (Nagelkerke's R2*100): 0.22 sex, age at study enrollment, genetic PCs 1-20
PPM002886 PSS001206|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Citalopram takers OR: 1.39 [1.08, 1.79] Variance explained (Nagelkerke's R2*100): 1.2 sex, age at study enrollment, genetic PCs 1-20
PPM002887 PSS001210|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Fluoxetine takers OR: 1.03 [0.85, 1.24] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002888 PSS001208|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Duloxetine takers OR: 1.04 [0.87, 1.26] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002889 PSS001212|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Paroxetine takers OR: 1.32 [1.0, 1.75] Variance explained (Nagelkerke's R2*100): 0.99 sex, age at study enrollment, genetic PCs 1-20
PPM002890 PSS001393|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Sertraline takers OR: 1.24 [1.14, 1.34] Variance explained (Nagelkerke's R2*100): 0.9 sex, age at study enrollment, genetic PCs 1-20
PPM002894 PSS001391|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Mirtazapine takers OR: 1.09 [0.94, 1.25] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002895 PSS001387|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Desvenlafaxine takers OR: 1.06 [0.94, 1.2] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002896 PSS001386|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Citalopram takers OR: 1.06 [0.92, 1.22] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002897 PSS001390|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Fluoxetine takers OR: 1.12 [1.02, 1.23] Variance explained (Nagelkerke's R2*100): 0.27 sex, age at study enrollment, genetic PCs 1-20
PPM002898 PSS001388|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Duloxetine takers OR: 0.98 [0.86, 1.12] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002899 PSS001392|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Paroxetine takers OR: 1.22 [1.05, 1.42] Variance explained (Nagelkerke's R2*100): 0.8 sex, age at study enrollment, genetic PCs 1-20
PPM002900 PSS001383|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Sertraline takers OR: 1.15 [1.01, 1.31] Variance explained (Nagelkerke's R2*100): 0.28 sex, age at study enrollment, genetic PCs 1-20
PPM002901 PSS001379|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Escitalopram takers OR: 1.06 [0.9, 1.24] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002902 PSS001384|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Venlafaxine takers OR: 1.36 [1.18, 1.58] Variance explained (Nagelkerke's R2*100): 1.35 sex, age at study enrollment, genetic PCs 1-20
PPM002903 PSS001375|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Amitriptyline takers OR: 0.97 [0.75, 1.24] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002904 PSS001381|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Mirtazapine takers OR: 1.11 [0.88, 1.4] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002905 PSS001377|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Desvenlafaxine takers OR: 0.97 [0.78, 1.21] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002906 PSS001376|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Citalopram takers OR: 0.96 [0.76, 1.21] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002907 PSS001380|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Fluoxetine takers OR: 1.09 [0.95, 1.26] Variance explained (Nagelkerke's R2*100): 0.11 sex, age at study enrollment, genetic PCs 1-20
PPM002908 PSS001378|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Duloxetine takers OR: 1.11 [0.89, 1.38] Variance explained (Nagelkerke's R2*100): 0.15 sex, age at study enrollment, genetic PCs 1-20
PPM002909 PSS001382|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide attempt in Paroxetine takers OR: 1.22 [0.95, 1.55] Variance explained (Nagelkerke's R2*100): 0.54 sex, age at study enrollment, genetic PCs 1-20
PPM002910 PSS001333|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Sertraline takers OR: 0.99 [0.91, 1.09] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002911 PSS001329|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Escitalopram takers OR: 0.96 [0.86, 1.07] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002912 PSS001334|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Venlafaxine takers OR: 1.14 [1.03, 1.27] Variance explained (Nagelkerke's R2*100): 0.31 sex, age at study enrollment, genetic PCs 1-20
PPM002913 PSS001325|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Amitriptyline takers OR: 1.07 [0.88, 1.29] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002914 PSS001331|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Mirtazapine takers OR: 1.03 [0.87, 1.2] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002915 PSS001327|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Desvenlafaxine takers OR: 1.02 [0.88, 1.18] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002916 PSS001326|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Citalopram takers OR: 0.95 [0.82, 1.1] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002917 PSS001330|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Fluoxetine takers OR: 1.05 [0.93, 1.18] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002918 PSS001328|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Duloxetine takers OR: 1.04 [0.89, 1.2] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002919 PSS001332|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Other side effects in Paroxetine takers OR: 0.97 [0.81, 1.16] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002920 PSS001323|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Sertraline takers OR: 1.04 [0.89, 1.21] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002921 PSS001319|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Escitalopram takers OR: 1.04 [0.89, 1.22] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002922 PSS001324|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Venlafaxine takers OR: 0.94 [0.79, 1.12] Variance explained (Nagelkerke's R2*100): 0.05 sex, age at study enrollment, genetic PCs 1-20
PPM002923 PSS001315|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Amitriptyline takers OR: 1.03 [0.84, 1.25] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002924 PSS001321|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Mirtazapine takers OR: 1.05 [0.83, 1.33] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002925 PSS001317|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Desvenlafaxine takers OR: 0.82 [0.68, 0.98] Variance explained (Nagelkerke's R2*100): 0.6 sex, age at study enrollment, genetic PCs 1-20
PPM002680 PSS001283|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Sertraline takers OR: 1.03 [0.95, 1.11] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002683 PSS001275|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Headaches in Amitriptyline takers OR: 0.96 [0.81, 1.12] Variance explained (Nagelkerke's R2*100): 0.04 sex, age at study enrollment, genetic PCs 1-20
PPM002706 PSS001366|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Shakes in Citalopram takers OR: 1.16 [0.98, 1.38] Variance explained (Nagelkerke's R2*100): 0.32 sex, age at study enrollment, genetic PCs 1-20
PPM002714 PSS001301|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Mirtazapine takers OR: 1.13 [0.9, 1.43] Variance explained (Nagelkerke's R2*100): 0.2 sex, age at study enrollment, genetic PCs 1-20
PPM002719 PSS001302|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Muscle pain in Paroxetine takers OR: 1.18 [0.87, 1.61] Variance explained (Nagelkerke's R2*100): 0.34 sex, age at study enrollment, genetic PCs 1-20
PPM002740 PSS001313|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Nausea in Sertraline takers OR: 1.08 [1.01, 1.15] Variance explained (Nagelkerke's R2*100): 0.13 sex, age at study enrollment, genetic PCs 1-20
PPM002753 PSS001415|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Vomit in Amitriptyline takers OR: 0.93 [0.65, 1.33] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002766 PSS001216|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Constipation in Citalopram takers OR: 1.02 [0.85, 1.22] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002770 PSS001233|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Diarrhoea in Sertraline takers OR: 1.05 [0.94, 1.16] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002781 PSS001249|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Drowsiness in Escitalopram takers OR: 0.96 [0.89, 1.05] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002799 PSS001412|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Trouble sleeping in Paroxetine takers OR: 1.06 [0.92, 1.22] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002815 PSS001187|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Agitation in Desvenlafaxine takers OR: 1.07 [0.94, 1.21] Variance explained (Nagelkerke's R2*100): 0.08 sex, age at study enrollment, genetic PCs 1-20
PPM002825 PSS001267|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Desvenlafaxine takers OR: 1.02 [0.91, 1.15] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002828 PSS001268|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Fatigue in Duloxetine takers OR: 0.93 [0.83, 1.04] Variance explained (Nagelkerke's R2*100): 0.14 sex, age at study enrollment, genetic PCs 1-20
PPM002830 PSS001433|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight gain in Sertraline takers OR: 1.02 [0.96, 1.08] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002843 PSS001435|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Weight loss in Amitriptyline takers OR: 1.09 [0.67, 1.78] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002850 PSS001343|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Sertraline takers OR: 1.04 [0.8, 1.36] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002851 PSS001339|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Rashes in Escitalopram takers OR: 1.09 [0.79, 1.5] Variance explained (Nagelkerke's R2*100): 0.07 sex, age at study enrollment, genetic PCs 1-20
PPM002866 PSS001356|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Citalopram takers OR: 1.05 [0.73, 1.51] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002867 PSS001360|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Runny nose in Fluoxetine takers OR: 1.03 [0.76, 1.4] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002874 PSS001351|
European Ancestry|
1,987 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Mirtazapine takers OR: 0.99 [0.9, 1.1] Variance explained (Nagelkerke's R2*100): 0.0 sex, age at study enrollment, genetic PCs 1-20
PPM002875 PSS001347|
European Ancestry|
2,524 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Desvenlafaxine takers OR: 1.11 [1.02, 1.21] Variance explained (Nagelkerke's R2*100): 0.34 sex, age at study enrollment, genetic PCs 1-20
PPM002876 PSS001346|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Citalopram takers OR: 1.1 [1.01, 1.2] Variance explained (Nagelkerke's R2*100): 0.28 sex, age at study enrollment, genetic PCs 1-20
PPM002877 PSS001350|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Reduced sexual desire in Fluoxetine takers OR: 1.05 [0.98, 1.12] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002880 PSS001213|
European Ancestry|
5,719 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Sertraline takers OR: 0.96 [0.83, 1.11] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002881 PSS001209|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Escitalopram takers OR: 1.03 [0.87, 1.22] Variance explained (Nagelkerke's R2*100): 0.01 sex, age at study enrollment, genetic PCs 1-20
PPM002882 PSS001214|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Blurry vision in Venlafaxine takers OR: 0.97 [0.84, 1.12] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20
PPM002891 PSS001389|
European Ancestry|
4,365 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Escitalopram takers OR: 1.09 [0.99, 1.2] Variance explained (Nagelkerke's R2*100): 0.15 sex, age at study enrollment, genetic PCs 1-20
PPM002892 PSS001394|
European Ancestry|
3,967 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Venlafaxine takers OR: 1.19 [1.09, 1.31] Variance explained (Nagelkerke's R2*100): 0.63 sex, age at study enrollment, genetic PCs 1-20
PPM002893 PSS001385|
European Ancestry|
1,657 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: Suicide thoughts in Amitriptyline takers OR: 0.94 [0.8, 1.11] Variance explained (Nagelkerke's R2*100): 0.06 sex, age at study enrollment, genetic PCs 1-20
PPM002926 PSS001316|
European Ancestry|
2,585 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Citalopram takers OR: 1.08 [0.92, 1.28] Variance explained (Nagelkerke's R2*100): 0.1 sex, age at study enrollment, genetic PCs 1-20
PPM002927 PSS001320|
European Ancestry|
3,670 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Fluoxetine takers OR: 1.05 [0.91, 1.21] Variance explained (Nagelkerke's R2*100): 0.03 sex, age at study enrollment, genetic PCs 1-20
PPM002928 PSS001318|
European Ancestry|
1,995 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Duloxetine takers OR: 0.91 [0.74, 1.13] Variance explained (Nagelkerke's R2*100): 0.12 sex, age at study enrollment, genetic PCs 1-20
PPM002929 PSS001322|
European Ancestry|
1,580 individuals
PGP000238 |
Campos AI et al. medRxiv (2021)
|Pre
Reported Trait: No side effects in Paroxetine takers OR: 0.97 [0.77, 1.22] Variance explained (Nagelkerke's R2*100): 0.02 sex, age at study enrollment, genetic PCs 1-20

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001185
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001186
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001187
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001188
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001189
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001190
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001191
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001192
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001193
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001194
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001195
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001196
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001197
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001198
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001199
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001200
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001201
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001202
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001203
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001204
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001205
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001206
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001207
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001208
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001209
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001210
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001211
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001212
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001213
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001214
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001215
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001216
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001217
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001218
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001219
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001220
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001221
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001222
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001223
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001224
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001225
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001226
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001227
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001228
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001229
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001230
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001231
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001232
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001233
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001234
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001235
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001236
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001237
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001238
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001239
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001240
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001241
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001242
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001243
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001244
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001245
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001246
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001247
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001248
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001249
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001250
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001251
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001252
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001253
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001254
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001255
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001256
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001257
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001258
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001259
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001260
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001261
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001262
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001263
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001264
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001265
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001266
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001267
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001268
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001269
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001270
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001271
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001272
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001273
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001274
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001275
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001276
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001277
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001278
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001279
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001280
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001281
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001282
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001283
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001284
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001295
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001296
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001297
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001298
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001299
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001300
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001301
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001302
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001303
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001304
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001305
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001306
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001307
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001308
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001309
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001310
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001311
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001312
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001313
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001314
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001315
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001316
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001317
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001318
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001319
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001320
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001321
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001322
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001323
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001324
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001325
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001326
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001327
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001328
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001329
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001330
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001331
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001332
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001333
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001334
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001335
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001336
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001337
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001338
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001339
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001340
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001341
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001342
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001343
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001344
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001345
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001346
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001347
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001348
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001349
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001350
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001351
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001352
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001353
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001354
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001355
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001356
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001357
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001358
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001359
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001360
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001361
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001362
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001363
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001364
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001365
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001366
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001367
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001368
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001369
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001370
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001371
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001372
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001373
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001374
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001375
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001376
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001377
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001378
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001379
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001380
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001381
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001382
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001383
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001384
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001385
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001386
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001387
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001388
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001389
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001390
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001391
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001392
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001393
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001394
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001395
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001396
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001397
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001398
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001399
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001400
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001401
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001402
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001403
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001404
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001405
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001406
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001407
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001408
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001409
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001410
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001411
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001412
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001413
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001414
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001415
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001416
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001417
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001418
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001419
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001420
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001421
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001422
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001423
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001424
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001425
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001426
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001427
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001428
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001429
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001430
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001431
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001432
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001433
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001434
[
  • 794 cases
  • , 3,173 controls
]
European AGDS
PSS001435
[
  • 140 cases
  • , 1,517 controls
]
European AGDS
PSS001436
[
  • 367 cases
  • , 2,218 controls
]
European AGDS
PSS001437
[
  • 489 cases
  • , 2,035 controls
]
European AGDS
PSS001438
[
  • 382 cases
  • , 1,613 controls
]
European AGDS
PSS001439
[
  • 712 cases
  • , 3,653 controls
]
European AGDS
PSS001440
[
  • 583 cases
  • , 3,087 controls
]
European AGDS
PSS001441
[
  • 186 cases
  • , 1,801 controls
]
European AGDS
PSS001442
[
  • 236 cases
  • , 1,344 controls
]
European AGDS
PSS001443
[
  • 1,020 cases
  • , 4,699 controls
]
European AGDS
PSS001444
[
  • 794 cases
  • , 3,173 controls
]
European AGDS